Condition
SARS COV-2 IgG Levels on Health Workers
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
1 treatments under study, led by Spike Protein S Or The Nucleocapsid N Of Sarscov2
Research Leaders
5 sponsors active, led by Baskent University
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Spike Protein S Or The Nucleocapsid N Of Sarscov21
Active Sponsors
- Baskent University1
- Zuhal Ekici Unsal1
- Hikmet Eda Aliskan1
- Hatice Hale Gumus1
- Ilker Odemis1